Indivior Share Holder Equity 2012-2024 | INDV

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Indivior share holder equity from 2012 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Indivior share holder equity from 2012 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$79.9B
Zoetis (ZTS)	$70.1B
Daiichi Sankyo, - (DSNKY)	$43.9B
Takeda Pharmaceutical (TAK)	$43.7B
Sandoz Group AG (SDZNY)	$20.6B
Merck (MKKGY)	$18.3B
Astellas Pharma (ALPMY)	$17.4B
United Therapeutics (UTHR)	$17B
Summit Therapeutics (SMMT)	$15.9B
Shionogi (SGIOY)	$12.3B
Neurocrine Biosciences (NBIX)	$11.4B
Corcept Therapeutics (CORT)	$7.7B
Madrigal Pharmaceuticals (MDGL)	$7.5B
Orion OYJ (ORINY)	$7.4B
Hikma Pharmaceuticals Plc (HKMPF)	$6.2B
Stevanato Group S.p.A (STVN)	$6.2B
Grifols, S.A (GRFS)	$5.1B
Ionis Pharmaceuticals (IONS)	$5B
Ono Pharmaceutical (OPHLF)	$4.7B
Recursion Pharmaceuticals (RXRX)	$4.2B
Crinetics Pharmaceuticals (CRNX)	$3.4B
Catalyst Pharmaceuticals (CPRX)	$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.4B
Hypermarcas (HYPMY)	$2.2B
Centessa Pharmaceuticals (CNTA)	$2.1B
Soleno Therapeutics (SLNO)	$2B
BioCryst Pharmaceuticals (BCRX)	$1.9B
NewAmsterdam Pharma (NAMS)	$1.8B
Evotec AG (EVO)	$1.6B
Ardelyx (ARDX)	$1.5B